HLA-C and neoplasm: Using MHC scores that reflect both the fraction of tumor cells expressing the marker and the level of expression, we found that the intact expression of MHC-I molecules on tumor cells was strongly associated with a response to anti-PD-1 monotherapy, but was not required for a response to combination immunotherapy.